Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (461-470 of 545) with videos related to

Pageof 55
Sort By:
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.
Gynecologic Oncology|July 1, 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyM Markman, E Rowinsky, T Hakes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancerM Markman, P Francis, E Rowinsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 10, 2006
Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research SymposiumM L Disis, S E Rivkin, A Baron, et al.
Journal of Biological Response Modifiers|October 1, 1986
Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphomaR O Dillman, J Beauregard, D L Shawler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupM Markman, B N Bundy, D S Alberts, et al.
Pageof 55

Showing results (461-470 of 545) with videos related to

Sort By:
Pageof 55
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.
Gynecologic Oncology|July 1, 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyM Markman, E Rowinsky, T Hakes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancerM Markman, P Francis, E Rowinsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 10, 2006
Progress in ovarian cancer research: proceedings of the 5th Biennial Ovarian Cancer Research SymposiumM L Disis, S E Rivkin, A Baron, et al.
Journal of Biological Response Modifiers|October 1, 1986
Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphomaR O Dillman, J Beauregard, D L Shawler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupM Markman, B N Bundy, D S Alberts, et al.
Pageof 55